DIRS.INFO The most relevant business & tech news

☆ UnitedHealth's first-quarter report will offer a window into Change cyberattack costs
▼ + stars: | 2024-04-15 | by ( Bertha Coombs | ) www.cnbc.com time to read: +2 min

"Everybody looks to United as the bellwether of all of health-care services. This will be different," said Lisa Gill, managing director and health care analyst at JPMorgan. The data breach at the Change Healthcare unit forced the firm to take down its massive billing and payment processing service. While the company has restored services for pharmacies, the outage has continued to disrupt operations for health-care providers across the country. Larger providers, such as home infusion services firm Option Care Health , have also warned that the outage could impact their quarterly results.

Persons: UnitedHealth Group's, Lisa Gill, Scott Fidel, UnitedHealth, they'd, James Allred, he's, Allred Organizations: JPMorgan, Healthcare, Optum, OptumRx, Stephens, American Medical Association, Aesthetics, Care Locations: Nashville

Goldman Sachs lowered its rating on Estée Lauder to neutral, and its new price target calls for a slight decline going forward. Elsewhere, Daiwa raised its price target on Nvidia, which points to more than 10% upside over the next 12 months. The firm stood by its outperform rating on the chipmaker stock, but lifted its price target to $900 from $535. FLYW YTD mountain FLYW in 2024 Faucette accompanied his downgrade by lifting his price target to $30 from $27. He also lifted his price target on the stock to $40 from $30, implying upside of 24.6% from Thursday's close.

Persons: Goldman Sachs, Estée Lauder, Jefferies, Root, Daiwa, Brad Sills, Sills, — Lisa Kailai Han, Stephens, Vita Coco, Coco, Jim Salera, COCO, Lisa Gill, Gill, Louis Miscioscia, Miscioscia, Lisa Kailai Han, Piper Sandler downgrades, Piper Sandler, Mark Fitzgibbon, Fitzgibbon, Morgan Stanley downgrades Flywire, Morgan Stanley, James Faucette, Faucette, Goldman Sachs downgrades Estée Lauder, Lauder, Goldman, Yaron Kinar, Kinar, Fred Imbert Organizations: CNBC, Nvidia, Bank of America, of America, Vertex, Accenture, RSM, BDO, JPMorgan, Daiwa, Markets, Riding, AMD, Intel, York Community Bancorp, York Community, New York Community Bancorp, Travel, B2B, U.S, Jefferies Locations: York, Canada, Asia, China, Hainan, Thursday's

CVS Health logo is seen displayed in this illustration taken, May 3, 2022. The regional health insurance provider will still retain CVS Caremark for managing specialty drugs, which are costly medications used to treat complex conditions like cancer and rheumatoid arthritis. Other analysts highlighted difficulties in shifting to a different model than the one offered by companies like CVS - which provide other services including home drug delivery and reimburse pharmacies for patients' prescriptions. Amazon Pharmacy will provide at-home delivery of prescription drugs as well as upfront pricing, while Mark Cuban Cost Plus Drug Company will provide access to generic drugs, Blue Shield said. Blue Shield of California's other partners include privately held Abarca for processing claims related to prescription drugs, while smaller PBM Prime Therapeutics will work to negotiate savings with drugmakers.

Persons: Dado Ruvic, Cigna, UnitedHealth, Mark, Elizabeth Anderson, J.P, Morgan, Lisa Gill, Gill, Blue, Manas Mishra, Mariam Sunny, Bhanvi, Shweta Agarwal, Pooja Desai, Krishna Chandra Eluri, Frances Kerry Organizations: CVS, REUTERS, Amazon, Cigna, UnitedHealth, Evercore ISI, Mark Cuban, Plus, Thomson Locations: Bengaluru

☆ Two health-care stocks are in the headlines. How the news impacts our investments
▼ + stars: | 2023-07-07 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

Here's a deeper look at the headlines and their implications for our investment theses in these two health-care companies. The Club's take: The first-of-their-kind FDA and CMS actions came in generally as anticipated, and represent incremental positives for Eli Lilly. That's why some of the decline seen Friday in Eli Lilly shares – down over 2%, to around $453 each – could simply represent a sell-the-news situation. Eli Lilly has said donanemab could be approved by the FDA late this year or in early 2024. Our expectations around donanemab sales also are measured, and the drug is not the primary driver of our multiyear optimism for Eli Lilly.

Persons: Eli Lilly, Eli Lilly's donanemab, Leqembi —, Biogen, —, Lilly's, That's, Donanemab, Lilly, donanemab, that's, Lisa Gill, UnitedHealth, Humana, Gill, What's, We'll, Jim Cramer's, Jim Cramer, Jim Organizations: Club, Drug Administration, Medicare, Medicaid Services, FDA, GE Healthcare, Humana, JPMorgan, CNBC Locations: Massachusetts

☆ This U.S. stock has risen 10% every year for the past decade — and analysts see more upside ahead
▼ + stars: | 2023-06-14 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

U.S. health insurance firm Humana is the only major stock from around the world to have risen by more than 10% every year for the past decade. Here's what some are saying: Deutsche Bank Equity analyst George Hill bumped up the bank's price target to $568 (10% upside) on April 26. RBC Capital Markets Ben Hendrix retired the bank's outperform rating and price target of $637 on April 27. The investment bank maintains an "in-line" or hold rating on the stock with a price target of $637. Jefferies' analysts raised their price target to $614 with a buy-rating on April 27.

Persons: —, Humana's, George Hill, JP Morgan Lisa Gill, HUM, UBS Kevin Caliendo, Ben Hendrix, Morgan Stanley's, Jefferies Organizations: Humana, CNBC Pro, Affordable, NYSE, Deutsche Bank Equity, MLR, UBS, Swiss, Medicare, RBC Locations: Kentucky, U.S

☆ Insurer Humana lifts profit view as medical costs drop in govt plans
▼ + stars: | 2023-04-26 | by ( ) www.reuters.com time to read: +2 min

April 26 (Reuters) - Humana Inc (HUM.N) raised its annual adjusted profit forecast on Wednesday after lower medical costs in the firm's government-backed health insurance business helped it beat profit estimates for the first quarter. That has driven increased investor scrutiny into whether one-time items are helping lower medical costs artificially, hurting shares of rivals UnitedHealth (UNH.N) and Elevance (ELV.N) earlier this month despite both beating profit estimates. Medicare Advantage is its main business of government-backed health insurance for the elderly or those with certain disabilities. The impact of its exit from the commercial business was not included in adjusted figures for the quarter, Humana said. Its adjusted profit came in at $9.38 per share, beating estimates of $9.27.

☆ Jim Cramer's top 10 things to watch in the market Friday: Goldilocks jobs, mega-caps, Costco
▼ + stars: | 2023-01-06 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Mega cap stock abandonment: Lots of hedge funds surprised Club holding Apple (AAPL) didn't go higher after it didn't preannounce. Club holding Costco (COST) says net sales of $23.8 billion for December rose 7% year over year. Guggenheim raises price target on Club holding Starbucks (SBUX) to $103 per share from $92; keeps hold-equivalent rating. Wells Fargo says the negativity is too great when it comes to PVH Corp (PVH) but raises price target and stock rating to a buy-equivalent. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Buy Walgreens as it ramps up its health care strategy, JPMorgan says in upgrade
▼ + stars: | 2022-11-18 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

It's time to buy Walgreens Boots Alliance as it makes notable progress in its health care strategy, according to JPMorgan. Analyst Lisa Gill upgraded the stock to overweight from neutral as the drugstore chain works to revamp its business and focus on health care. "The faster than expected ramp in Walgreens Healthcare, creates the potential for the segment to be a material contributor in the medium-term," she added. This month, VillageMD, a primary care company that is majority owned by Walgreens, said it's acquiring Summit Health, the parent company of urgent care clinics CityMD, for $8.9 billion. Walgreens' other acquisitions include acquiring CareCentrix , an at-home care company.

People are seen shopping in a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly/File PhotoOct 13 (Reuters) - Walgreens Boots Alliance Inc (WBA.O) reported a better-than-expected quarterly profit on Thursday, as higher UK retail sales helped more than offset waning COVID vaccination demand. Shares of Walgreens, one of the largest U.S. pharmacies, rose nearly 3% amid bigger market weakness after the company also forecast a "better-than-feared" full-year profit. Register now for FREE unlimited access to Reuters.com RegisterDespite inflationary challenges, Walgreens saw an uptick in retail sales, helped by higher demand for health and wellness as well as beauty products. The company also benefited from its Walgreens Health segment, which was launched last year as part of Walgreens' efforts to diversify its business.

Search resuls for: "Lisa Gill"

9 mentions found